ARTICLE | Product Development
Synlogic’s mathematical models guide its next act in engineered bacterial therapies
What Synlogic is learning from its second stab at engineered bacterial therapy
August 4, 2021 8:08 PM UTC
Synlogic is starting to see proof of mechanism for its second shot at engineered bacterial therapy, but the company’s mathematical model suggests overcoming therapeutic window constraints will require investing in its next generation version of the program.
Founded in 2014 to engineer microbes that perform therapeutic functions, Synlogic Inc. (NASDAQ:SYBX) has already faced the need to make go/no-go decisions based on early clinical data; in 2019, the company axed its lead candidate SYNB1020 based on interim Phase Ib/IIa data showing the hyperammonemia therapy did not affect key exploratory endpoints, despite showing pharmacodynamic activity...